Actinogen Medical Ltd Sustainability Reports
Actinogen Medical Limited is a clinical-stage biotechnology company focused on developing novel therapies for neurological and neuropsychiatric diseases. Its lead compound, emestedastat (Xanamem), is designed to inhibit cortisol production in brain cells to treat conditions such as Alzheimer's disease and major depressive disorder.
Sector: Manufacturing
Country: Australia
Exchange: Australian Securities Exchange
FIGI: BBG001SRC0W8
6 reports from 2017 to 2023
